FibroGen Inks Clinical Trial Supply Agreement With Regeneron Pharmaceuticals To Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 And FG-3175, In Combination With LIBTAYO In Upcoming Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
FibroGen has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate its immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO, in patients with solid tumors.

June 03, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FibroGen has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate its immuno-oncology assets, FG-3165 and FG-3175, in combination with LIBTAYO.
The partnership with Regeneron to evaluate FG-3165 and FG-3175 in combination with LIBTAYO could potentially enhance FibroGen's product pipeline and market position in the immuno-oncology space.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Regeneron Pharmaceuticals has entered into a clinical trial supply agreement with FibroGen to evaluate LIBTAYO in combination with FibroGen's immuno-oncology assets, FG-3165 and FG-3175.
The collaboration with FibroGen to test LIBTAYO in combination with new immuno-oncology assets could potentially expand Regeneron's therapeutic offerings and strengthen its position in the oncology market.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80